Certara, Inc. (NASDAQ:CERT) Short Interest Update

Certara, Inc. (NASDAQ:CERT) was the recipient of a significant decline in short interest during the month of August. As of August 31st, there was short interest totalling 6,520,000 shares, a decline of 5.5% from the August 15th total of 6,900,000 shares. Based on an average daily volume of 895,600 shares, the days-to-cover ratio is presently 7.3 days. Approximately 6.0% of the shares of the stock are sold short.

Analysts Set New Price Targets

Several research analysts recently commented on CERT shares. Jefferies Financial Group lowered Certara from a “buy” rating to a “hold” rating and dropped their price target for the stock from $24.50 to $17.00 in a research report on Tuesday, August 22nd. William Blair lowered Certara from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 10th. Bank of America dropped their price target on Certara from $27.00 to $24.00 and set a “buy” rating for the company in a research report on Tuesday, August 15th. Barclays dropped their price target on Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday, August 11th. Finally, TheStreet lowered Certara from a “c-” rating to a “d+” rating in a research report on Friday, June 16th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Certara presently has a consensus rating of “Hold” and a consensus price target of $20.86.

Insider Transactions at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $14.60, for a total value of $747,870.40. Following the sale, the insider now directly owns 128,883 shares of the company’s stock, valued at $1,881,691.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CERT. Tower Research Capital LLC TRC grew its stake in Certara by 584.8% in the second quarter. Tower Research Capital LLC TRC now owns 1,356 shares of the company’s stock worth $25,000 after purchasing an additional 1,158 shares in the last quarter. Harvest Fund Management Co. Ltd bought a new position in Certara in the first quarter worth approximately $37,000. State of Wyoming grew its stake in Certara by 103.1% in the second quarter. State of Wyoming now owns 2,027 shares of the company’s stock worth $37,000 after purchasing an additional 1,029 shares in the last quarter. OLD Mission Capital LLC bought a new position in Certara in the fourth quarter worth approximately $49,000. Finally, HighMark Wealth Management LLC bought a new position in Certara in the first quarter worth approximately $53,000. Institutional investors own 67.26% of the company’s stock.

Certara Trading Down 0.9 %

CERT opened at $13.98 on Tuesday. The stock has a market cap of $2.23 billion, a price-to-earnings ratio of 116.51, a P/E/G ratio of 0.97 and a beta of 1.46. The stock’s 50 day moving average price is $17.11 and its 200-day moving average price is $19.77. Certara has a one year low of $10.60 and a one year high of $24.96. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.43 and a current ratio of 3.43.

Certara (NASDAQ:CERT) last released its earnings results on Wednesday, August 9th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.02. The firm had revenue of $90.45 million for the quarter, compared to analysts’ expectations of $92.04 million. Certara had a return on equity of 5.56% and a net margin of 5.45%. On average, equities analysts forecast that Certara will post 0.34 EPS for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.